Trial Profile

VRC 608: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jan 2019 Results assessing safety,tolerability, pharmacokinetics and immunogenecity published in the Lancet.
24 Jan 2019 According to a National Institute of Allergy and Infectious Diseases Media Release, the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) conducted and sponsored the clinical trial.
24 Jan 2019 Results published in the National Institute of Allergy and Infectious Diseases Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com